Production (Stage)
Ondine Biomedical Inc.
OBIMF
$0.14
$0.00392.87%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 49.26% | 50.99% | 97.05% | 101.39% | 105.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.26% | 50.99% | 97.05% | 101.39% | 105.63% |
| Cost of Revenue | 19.80% | 21.18% | 83.00% | 87.16% | 38.34% |
| Gross Profit | 70.32% | 72.28% | 106.96% | 111.42% | 215.18% |
| SG&A Expenses | 51.40% | 53.20% | -19.02% | -17.25% | -39.82% |
| Depreciation & Amortization | -7.40% | -6.32% | -9.14% | -7.18% | 16.15% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.83% | 66.78% | 0.85% | 3.06% | -29.82% |
| Operating Income | -66.61% | -68.58% | 4.27% | 2.18% | 34.74% |
| Income Before Tax | -69.18% | -71.19% | 3.54% | 1.43% | 39.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.18% | -71.19% | 3.54% | 1.43% | 39.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.18% | -71.19% | 3.54% | 1.43% | 39.85% |
| EBIT | -66.61% | -68.58% | 4.27% | 2.18% | 34.74% |
| EBITDA | -67.35% | -69.34% | 4.02% | 1.92% | 34.99% |
| EPS Basic | -10.00% | -10.66% | 22.52% | 20.67% | 41.18% |
| Normalized Basic EPS | -5.13% | -6.33% | 23.16% | 20.21% | 38.58% |
| EPS Diluted | -10.00% | -10.66% | 22.52% | 20.67% | 41.18% |
| Normalized Diluted EPS | -5.13% | -6.33% | 23.16% | 20.21% | 38.58% |
| Average Basic Shares Outstanding | 54.25% | 54.25% | 24.01% | 24.01% | 2.53% |
| Average Diluted Shares Outstanding | 54.25% | 54.25% | 24.01% | 24.01% | 2.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |